OREANDA-NEWS. The vaccine against the coronavirus infection AZD1222 being developed in Great Britain has shown high efficacy during tests, the pharmaceutical company AstraZeneca reported. It was explained that the tests included two variants of the vaccination, which demonstrated different effectiveness.

In the first case, more than 2.7 thousand people received AZD1222 in a half dose, and a month later in full. This method of vaccination showed an efficiency of 90 %, while with a difference in a month, the introduction of almost 9 thousand people with the full dose showed just 62 %. Thus, the average vaccine efficacy for both tests is 70 %, AstraZeneca informed.

According to Professor Andrew Pollard, who led the vaccine trials in Oxford, the test results confirmed that AZD1222 could save many lives. “Excitingly, we’ve found that one of our dosing regimens may be around 90 % effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply,” he said.